<DOC>
	<DOCNO>NCT01789437</DOCNO>
	<brief_summary>evaluate wall-to-lumen ratio ( WLR ) retinal arteriole hypertensive patient retinal vein occlusion ( RVO ) dexamethasone intravitreal implant 0.7 mg ( DEX ) compare match control group normal eye non-hypertensive subject .</brief_summary>
	<brief_title>Diameters Wall-to-lumen Ratio Retinal Arterioles Patients With Retinal Vein Occlusion .</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>ability provide write informed consent comply study assessment full duration study ; age &gt; 20 year ; decrease visual acuity result clinically detectable ME associate either CRVO BRVO ; duration macular edema require 4 24 week CRVO BRVO ; retinal thickness central subfield ( measure use optical coherence tomography ) &gt; 350 Âµm study eye . exclusion criterion follow : diabetes ; previous intravitreal antiVEGF therapy intravitreal steroid therapy ; previous photodynamic therapy focal laser ; active retinal optic disc neovascularization ; active history choroidal neovascularization ; presence rubeosis iridis ; active infection ; glaucoma , current ocular hypertension , history steroidinduced intraocular pressure ( IOP ) increase either eye ; concurrent eye disease study eye could compromise visual acuity ( e.g. , choroidal neovascularization , diabetic retinopathy , epiretinal membrane ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>retinal vein occlusion</keyword>
	<keyword>systemic hypertension</keyword>
	<keyword>arteriolar diameter</keyword>
</DOC>